IRIDEX reported a narrower year-over-year net loss per share in Q1'26, helped by strong glaucoma product sales and lower operating costs. Weakness in retina sales and supply-chain disruptions offset some of the improvement, making the quarter mixed but modestly better overall.
IRIDEX reported a narrower year-over-year net loss per share in Q1'26, helped by strong glaucoma product sales and lower operating costs. Weakness in retina sales and supply-chain disruptions offset some of the improvement, making the quarter mixed but modestly better overall.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
